Published in Curr Drug Targets on March 01, 2013
Neutrophil roles in left ventricular remodeling following myocardial infarction. Fibrogenesis Tissue Repair (2013) 0.99
Myocardial matrix metalloproteinase-2: inside out and upside down. J Mol Cell Cardiol (2014) 0.88
The crossroads of inflammation, fibrosis, and arrhythmia following myocardial infarction. J Mol Cell Cardiol (2015) 0.87
The circular relationship between matrix metalloproteinase-9 and inflammation following myocardial infarction. IUBMB Life (2015) 0.78
MMP-9 signaling in the left ventricle following myocardial infarction. Am J Physiol Heart Circ Physiol (2016) 0.76
Role of matrix metalloproteinase-8 as a mediator of injury in intestinal ischemia and reperfusion. FASEB J (2016) 0.75
Gene Therapy With Angiotensin-(1-9) Preserves Left Ventricular Systolic Function After Myocardial Infarction. J Am Coll Cardiol (2016) 0.75
Relationship among LRP1 expression, Pyk2 phosphorylation and MMP-9 activation in left ventricular remodelling after myocardial infarction. J Cell Mol Med (2017) 0.75
Cutaneous wound healing. N Engl J Med (1999) 19.12
The myofibroblast: one function, multiple origins. Am J Pathol (2007) 8.64
Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation (2000) 7.12
Collagens: molecular biology, diseases, and potentials for therapy. Annu Rev Biochem (1995) 5.52
Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol (1999) 4.99
Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell (2002) 4.89
Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest (2000) 4.79
Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev (2007) 4.69
Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther (2009) 4.21
Macrophages and angiogenesis. J Leukoc Biol (1994) 3.85
Proteoglycan-fibrillar collagen interactions. Biochem J (1988) 3.76
Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Invest (1996) 3.42
Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov (2007) 3.36
SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest (2001) 3.13
Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol (2009) 2.93
Growth factors in the extracellular matrix. FASEB J (1997) 2.71
Contribution of monocytes/macrophages to compensatory neovascularization: the drilling of metalloelastase-positive tunnels in ischemic myocardium. Circ Res (2000) 2.66
Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med (2002) 2.59
A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J Neurosci (2005) 2.54
Collagen remodeling after myocardial infarction in the rat heart. Am J Pathol (1995) 2.46
Mechanisms of force generation and transmission by myofibroblasts. Curr Opin Biotechnol (2003) 2.43
Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke (2002) 2.30
Macrophage roles following myocardial infarction. Int J Cardiol (2008) 2.14
An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation (2001) 2.09
The infarcted myocardium: simply dead tissue, or a lively target for therapeutic interventions. Cardiovasc Res (1999) 2.06
Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. Circulation (1999) 2.06
SPARC, a matricellular protein: at the crossroads of cell-matrix. Matrix Biol (2000) 2.03
Matricellular proteins in cardiac adaptation and disease. Physiol Rev (2012) 2.01
Molecular Recognition of Proteinminus signLigand Complexes: Applications to Drug Design. Chem Rev (1997) 2.01
Measured versus self-reported compliance with doxycycline therapy for chlamydia-associated syndromes: high therapeutic success rates despite poor compliance. Sex Transm Dis (1999) 1.99
Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke (2003) 1.95
Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J Clin Invest (2005) 1.94
Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med (1996) 1.93
Mechanical interactions between collagen and proteoglycans: implications for the stability of lung tissue. J Appl Physiol (1985) (2004) 1.85
Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9. Cardiovasc Res (2002) 1.83
Masters and servants of the force: the role of matrix adhesions in myofibroblast force perception and transmission. Eur J Cell Biol (2005) 1.77
N-H...O, O-H...O, and C-H...O hydrogen bonds in protein-ligand complexes: strong and weak interactions in molecular recognition. Proteins (2004) 1.75
Integrin-mediated interactions between human bone marrow stromal precursor cells and the extracellular matrix. Bone (2001) 1.74
Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res (2000) 1.69
The effect of hyaluronate and its oligosaccharides on endothelial cell proliferation and monolayer integrity. Exp Cell Res (1989) 1.67
Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease. J Am Coll Cardiol (2002) 1.66
Aspirin inhibits ox-LDL-mediated LOX-1 expression and metalloproteinase-1 in human coronary endothelial cells. Cardiovasc Res (2004) 1.62
Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction. J Exp Med (2008) 1.62
Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation (2001) 1.59
Contribution of impaired mitochondrial autophagy to cardiac aging: mechanisms and therapeutic opportunities. Circ Res (2012) 1.53
Angiotensin II receptor blocker reduces oxidative stress and attenuates hypoxia-induced left ventricular remodeling in apolipoprotein E-knockout mice. Hypertens Res (2007) 1.51
Matrix metalloproteinase-7 affects connexin-43 levels, electrical conduction, and survival after myocardial infarction. Circulation (2006) 1.46
Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol (2003) 1.45
Extracellular matrix, inflammation, and the angiogenic response. Cardiovasc Res (2010) 1.45
Macrophage-stimulated cardiac fibroblast production of IL-6 is essential for TGF β/Smad activation and cardiac fibrosis induced by angiotensin II. PLoS One (2012) 1.43
Proteomic analysis identifies in vivo candidate matrix metalloproteinase-9 substrates in the left ventricle post-myocardial infarction. Proteomics (2010) 1.42
Extracellular matrix remodeling following myocardial injury. Ann Med (2003) 1.41
Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts. Am J Physiol Heart Circ Physiol (2005) 1.40
Tenascin and fibronectin expression in healing human myocardial scars. J Pathol (1996) 1.40
Temporal and spatial expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases following myocardial infarction. Cardiovasc Ther (2010) 1.39
Cardiac fibroblast to myofibroblast differentiation in vivo and in vitro: expression of focal adhesion components in neonatal and adult rat ventricular myofibroblasts. Dev Dyn (2010) 1.33
Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev (2004) 1.27
Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. Arthritis Rheum (2003) 1.26
Macrophage elastase (MMP-12): a pro-inflammatory mediator? Mem Inst Oswaldo Cruz (2005) 1.23
Topography of extracellular matrix mediates vascular morphogenesis and migration speeds in angiogenesis. PLoS Comput Biol (2009) 1.23
X-ray absorption studies of human matrix metalloproteinase-2 (MMP-2) bound to a highly selective mechanism-based inhibitor. comparison with the latent and active forms of the enzyme. J Biol Chem (2001) 1.21
Macrophage-dependent regulation of syndecan gene expression. Circ Res (1997) 1.15
Syndecan-4 prevents cardiac rupture and dysfunction after myocardial infarction. Circ Res (2011) 1.12
The design, structure, and therapeutic application of matrix metalloproteinase inhibitors. Curr Med Chem (2001) 1.12
Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodelling and all-cause mortality after acute myocardial infarction. Eur J Heart Fail (2008) 1.11
The role of the thrombospondins in healing myocardial infarcts. Cardiovasc Hematol Agents Med Chem (2007) 1.10
Matrix metalloproteinase-28 deletion amplifies inflammatory and extracellular matrix responses to cardiac aging. Microsc Microanal (2011) 1.09
Macrophage colony-stimulating factor treatment after myocardial infarction attenuates left ventricular dysfunction by accelerating infarct repair. J Am Coll Cardiol (2006) 1.08
Aldosterone stimulates matrix metalloproteinases and reactive oxygen species in adult rat ventricular cardiomyocytes. Hypertension (2005) 1.08
Tissue inhibitor of metalloproteinase-4 instigates apoptosis in transformed cardiac fibroblasts. J Cell Biochem (2001) 1.06
Thrombospondin-1 is induced in rat myocardial infarction and its induction is accelerated by ischemia/reperfusion. Exp Biol Med (Maywood) (2005) 1.03
Matrix metalloproteinases in cardiovascular disease. Can J Cardiol (2006) 1.03
Matrix metalloproteinase-9 promotes neutrophil and T cell recruitment and migration in the postischemic liver. J Leukoc Biol (2006) 1.03
SPARC upregulates MT1-MMP expression, MMP-2 activation, and the secretion and cleavage of galectin-3 in U87MG glioma cells. Neurosci Lett (2007) 1.01
Matrix metalloproteinases and myocardial infarction. Can J Cardiol (2007) 1.01
Accumulation of fibronectin in the heart after myocardial infarction: a putative stimulator of adhesion and proliferation of adipose-derived stem cells. Cell Tissue Res (2008) 1.01
Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results. Curr Med Chem (2005) 1.00
SPARC regulates collagen interaction with cardiac fibroblast cell surfaces. Am J Physiol Heart Circ Physiol (2011) 1.00
Local complement activation triggers neutrophil recruitment to the site of thrombus formation in acute myocardial infarction. Thromb Haemost (2009) 1.00
Interleukin-1alpha stimulates proinflammatory cytokine expression in human cardiac myofibroblasts. Am J Physiol Heart Circ Physiol (2009) 1.00
Inflammation and ischemia: macrophages activated by fibronectin fragments enhance the survival of injured cardiac myocytes. Exp Biol Med (Maywood) (2004) 1.00
Differentiation of human adipose-derived stem cells towards cardiomyocytes is facilitated by laminin. Cell Tissue Res (2008) 1.00
Complement activation and inhibition in myocardial ischemia and reperfusion injury. Annu Rev Pharmacol Toxicol (1994) 0.99
Nonsteroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 via suppression of the ERK/Sp1-mediated transcription. J Biol Chem (2002) 0.99
Cardiac rupture after myocardial infarction: new insights from murine models. Cardiol Rev (2009) 0.97
Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation (2004) 0.97
Increased expression of fibronectin isoforms after myocardial infarction in rats. J Mol Cell Cardiol (1997) 0.95
In vivo matrix metalloproteinase-7 substrates identified in the left ventricle post-myocardial infarction using proteomics. J Proteome Res (2010) 0.95
Remodeling MMPIs. Biotechnology (N Y) (1995) 0.95
Association of neutrophil/lymphocyte ratio with long-term mortality after ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Chin Med J (Engl) (2010) 0.95
Expression profiles of matrix metalloproteinases and their inhibitors in colonic inflammation related to pediatric inflammatory bowel disease. Scand J Gastroenterol (2010) 0.94
Increase in plasma matrix metalloproteinase-9 in acute stroke patients with thrombolysis failure. Stroke (2003) 0.94
beta-blockade prevents sustained metalloproteinase activation and diastolic stiffening induced by angiotensin II combined with evolving cardiac dysfunction. Circ Res (2000) 0.94
Simvastatin inhibits TNFalpha-induced invasion of human cardiac myofibroblasts via both MMP-9-dependent and -independent mechanisms. J Mol Cell Cardiol (2007) 0.94
Mechanism-based inhibition of zinc proteases. Curr Med Chem (2001) 0.93
Role of extracellular matrix proteins in heart function. Mol Cell Biochem (1993) 0.93
The extracellular matrix in normal and diseased myocardium. J Nucl Cardiol (2001) 0.93
Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension. Br J Pharmacol (2010) 0.92
Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration. Int J Cardiol (2004) 0.92
Macrophage roles following myocardial infarction. Int J Cardiol (2008) 2.14
Matrix metalloproteinase-28 deletion exacerbates cardiac dysfunction and rupture after myocardial infarction in mice by inhibiting M2 macrophage activation. Circ Res (2012) 1.94
Multi-analyte profiling reveals matrix metalloproteinase-9 and monocyte chemotactic protein-1 as plasma biomarkers of cardiac aging. Circ Cardiovasc Genet (2011) 1.73
Transgenic overexpression of matrix metalloproteinase-9 in macrophages attenuates the inflammatory response and improves left ventricular function post-myocardial infarction. J Mol Cell Cardiol (2012) 1.69
Effects of early and late chronic pressure overload on extracellular matrix remodeling. Hypertens Res (2008) 1.47
Proteomic analysis identifies in vivo candidate matrix metalloproteinase-9 substrates in the left ventricle post-myocardial infarction. Proteomics (2010) 1.42
Matrix metalloproteinase-9: Many shades of function in cardiovascular disease. Physiology (Bethesda) (2013) 1.41
Altered fibroblast function following myocardial infarction. J Mol Cell Cardiol (2005) 1.37
Extracellular matrix roles during cardiac repair. Life Sci (2010) 1.32
Extracellular matrix turnover and signaling during cardiac remodeling following MI: causes and consequences. J Mol Cell Cardiol (2009) 1.31
Matrix metalloproteinase-9 deletion attenuates myocardial fibrosis and diastolic dysfunction in ageing mice. Cardiovasc Res (2012) 1.25
The history of matrix metalloproteinases: milestones, myths, and misperceptions. Am J Physiol Heart Circ Physiol (2012) 1.22
Deletion of thioredoxin-interacting protein in mice impairs mitochondrial function but protects the myocardium from ischemia-reperfusion injury. J Clin Invest (2011) 1.21
Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. Pharmacol Ther (2013) 1.21
Age-related cardiac muscle sarcopenia: Combining experimental and mathematical modeling to identify mechanisms. Exp Gerontol (2007) 1.20
Long-lived ames dwarf mice are resistant to chemical stressors. J Gerontol A Biol Sci Med Sci (2009) 1.18
Effects of deletion of the matrix metalloproteinase 9 gene on development of murine thoracic aortic aneurysms. Circulation (2005) 1.15
CC chemokine receptor 5 deletion impairs macrophage activation and induces adverse remodeling following myocardial infarction. Am J Physiol Heart Circ Physiol (2011) 1.13
The cardiovascular effects of GLP-1 receptor agonists. Cardiovasc Ther (2010) 1.12
PROactive: time for a critical appraisal. Eur Heart J (2008) 1.11
Matrix metalloproteinase-28 deletion amplifies inflammatory and extracellular matrix responses to cardiac aging. Microsc Microanal (2011) 1.09
Alterations in cultured myocardial fibroblast function following the development of left ventricular failure. J Mol Cell Cardiol (2006) 1.08
Monoamine oxidase B prompts mitochondrial and cardiac dysfunction in pressure overloaded hearts. Antioxid Redox Signal (2013) 1.04
The left ventricle proteome differentiates middle-aged and old left ventricles in mice. J Proteome Res (2008) 1.04
Texas 3-step decellularization protocol: looking at the cardiac extracellular matrix. J Proteomics (2013) 1.01
Neutrophil roles in left ventricular remodeling following myocardial infarction. Fibrogenesis Tissue Repair (2013) 0.99
Myofibroblasts and the extracellular matrix network in post-myocardial infarction cardiac remodeling. Pflugers Arch (2014) 0.98
Reduced BDNF attenuates inflammation and angiogenesis to improve survival and cardiac function following myocardial infarction in mice. Am J Physiol Heart Circ Physiol (2013) 0.97
Transformative Impact of Proteomics on Cardiovascular Health and Disease: A Scientific Statement From the American Heart Association. Circulation (2015) 0.96
In vivo matrix metalloproteinase-7 substrates identified in the left ventricle post-myocardial infarction using proteomics. J Proteome Res (2010) 0.95
Inhibiting metalloproteases with PD 166793 in heart failure: impact on cardiac remodeling and beyond. Cardiovasc Ther (2008) 0.94
Toll-like receptor (TLR) 2 and TLR4 differentially regulate doxorubicin induced cardiomyopathy in mice. PLoS One (2012) 0.94
Extracellular matrix and fibroblast communication following myocardial infarction. J Cardiovasc Transl Res (2012) 0.93
SPARC mediates early extracellular matrix remodeling following myocardial infarction. Am J Physiol Heart Circ Physiol (2011) 0.90
Mathematical modeling and stability analysis of macrophage activation in left ventricular remodeling post-myocardial infarction. BMC Genomics (2012) 0.89
Getting to the heart of the matter: age-related changes in diastolic heart function in the longest-lived rodent, the naked mole rat. J Gerontol A Biol Sci Med Sci (2012) 0.89
Walking the oxidative stress tightrope: a perspective from the naked mole-rat, the longest-living rodent. Curr Pharm Des (2011) 0.88
Combining experimental and mathematical modeling to reveal mechanisms of macrophage-dependent left ventricular remodeling. BMC Syst Biol (2011) 0.88
Citrate synthase is a novel in vivo matrix metalloproteinase-9 substrate that regulates mitochondrial function in the postmyocardial infarction left ventricle. Antioxid Redox Signal (2014) 0.88
Heart failure with preserved ejection fraction: emerging drug strategies. J Cardiovasc Pharmacol (2013) 0.87
Effects of surface-modified scaffolds on the growth and differentiation of mouse adipose-derived stromal cells. J Tissue Eng Regen Med (2007) 0.86
Cardiac extracellular proteome profiling and membrane topology analysis using glycoproteomics. Proteomics Clin Appl (2014) 0.86
Mathematical modeling of left ventricular dimensional changes in mice during aging. BMC Syst Biol (2012) 0.85
Applications of miRNA technology for atherosclerosis. Curr Atheroscler Rep (2014) 0.84
Translating Koch's postulates to identify matrix metalloproteinase roles in postmyocardial infarction remodeling: cardiac metalloproteinase actions (CarMA) postulates. Circ Res (2014) 0.84
Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. Clin Ther (2003) 0.84
Proteomic analysis reveals late exercise effects on cardiac remodeling following myocardial infarction. J Proteomics (2010) 0.84
Cardioprotection: the role of beta-blocker therapy. J Clin Hypertens (Greenwich) (2005) 0.84
Alterations in Pulse Pressure Affect Artery Function. Cell Mol Bioeng (2012) 0.84
Alterations of pulse pressure stimulate arterial wall matrix remodeling. J Biomech Eng (2009) 0.84
Artery buckling stimulates cell proliferation and NF-κB signaling. Am J Physiol Heart Circ Physiol (2014) 0.83
Cardiac wound healing post-myocardial infarction: a novel method to target extracellular matrix remodeling in the left ventricle. Methods Mol Biol (2013) 0.83
Using proteomics to uncover extracellular matrix interactions during cardiac remodeling. Proteomics Clin Appl (2013) 0.83
ACE inhibitors to block MMP-9 activity: new functions for old inhibitors. J Mol Cell Cardiol (2007) 0.82
Bayesian parameter estimation for nonlinear modelling of biological pathways. BMC Syst Biol (2011) 0.82
Cardiac function of the naked mole-rat: ecophysiological responses to working underground. Am J Physiol Heart Circ Physiol (2013) 0.82
Roles of saturated vs. polyunsaturated fat in heart failure survival: not all fats are created equal. Cardiovasc Res (2011) 0.81
DHA derivatives of fish oil as dietary supplements: a nutrition-based drug discovery approach for therapies to prevent metabolic cardiotoxicity. Expert Opin Drug Discov (2012) 0.81
Mechanisms to inhibit matrix metalloproteinase activity: where are we in the development of clinically relevant inhibitors? Recent Pat Anticancer Drug Discov (2007) 0.81
Plasma fractionation enriches post-myocardial infarction samples prior to proteomics analysis. Int J Proteomics (2012) 0.80
Estrogen effects on MMP-13 and MMP-14 regulation of left ventricular mass in Dahl salt-induced hypertension. Gend Med (2008) 0.80
A conceptual cellular interaction model of left ventricular remodelling post-MI: dynamic network with exit-entry competition strategy. BMC Syst Biol (2010) 0.80
Left ventricular remodeling: one small step for the extracellular matrix will translate to a giant leap for the myocardium. Congest Heart Fail (2013) 0.80
Using systems biology approaches to understand cardiac inflammation and extracellular matrix remodeling in the setting of myocardial infarction. Wiley Interdiscip Rev Syst Biol Med (2014) 0.80
Plasma monitoring of the myocardial specific tissue inhibitor of metalloproteinase-4 after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. J Card Fail (2005) 0.80
Chronic and intermittent hypoxia differentially regulate left ventricular inflammatory and extracellular matrix responses. Hypertens Res (2012) 0.80
Understanding the role of the extracellular matrix in cardiovascular development and disease: where do we go from here? J Mol Cell Cardiol (2009) 0.80
A two-for-one bargain: using cilnidipine to treat hypertension and its comorbidities. J Clin Hypertens (Greenwich) (2013) 0.79
Obese and diabetic KKAy mice show increased mortality but improved cardiac function following myocardial infarction. Cardiovasc Pathol (2013) 0.79
Proteomic analysis of the left ventricle post-myocardial infarction to identify in vivo candidate matrix metalloproteinase substrates. Methods Mol Biol (2013) 0.78
Fish oil decreases inflammation and reduces cardiac remodeling in rosiglitazone treated aging mice. Pharmacol Res (2010) 0.78
Is isolated systolic hypertension worse than combined systolic/diastolic hypertension? J Clin Hypertens (Greenwich) (2012) 0.78
Cardiac assessment in pediatric mice: strain analysis as a diagnostic measurement. Echocardiography (2013) 0.78
Comparative proteome analysis of splenic lymphocytes in senescence-accelerated mice. Gerontology (2009) 0.78
Thrombospondin-1: the good, the bad, and the complicated. Circ Res (2013) 0.78
Diabetic endovascular disease: role of coronary artery revascularization. Am J Cardiol (2006) 0.78
Comparison of two tandem mass spectrometry-based methods for analyzing the proteome of healthy human lens fibers. Mol Vis (2007) 0.78
Titin phosphorylation: myocardial passive stiffness regulated by the intracellular giant. Circ Res (2009) 0.78
HDL-cholesterol levels and cardiovascular risk: acCETPing the context. Eur Heart J (2008) 0.78
Heart rate reduction: an old and novel candidate heart failure therapy. Hypertension (2012) 0.77
Crosstalk between cytotoxic T-lymphocyte associated antigen-4 and interleukin-12 in cytotoxic T-lymphocyte-mediated myocarditis: adding another link to the chain. Circ Res (2007) 0.77
Functional phosphoproteomic analysis reveals that a serine-62-phosphorylated isoform of ethylene response factor110 is involved in Arabidopsis bolting. Plant Physiol (2012) 0.77
Extracellular matrix proteomics in cardiac ischemia/reperfusion: the search is on. Circulation (2012) 0.76
Antibody-free detection of Mycobacterium tuberculosis antigen using customized nanotraps. Anal Chem (2014) 0.76
Systems analysis of gene ontology and biological pathways involved in post-myocardial infarction responses. BMC Genomics (2015) 0.76
Tumor necrosis factor-alpha--converting enzyme roles in hypertension-induced hypertrophy: look both ways when crossing the street. Hypertension (2009) 0.75
Heavy hitting: Using water to label humans. Proteomics Clin Appl (2014) 0.75
Going out on a LIM and cysteine-rich domains 1 limb: a new way to block calcineurin activity. Hypertension (2009) 0.75
AMP activated protein kinase 2 protection during hypertension-induced hypertrophy: a common mediator in the signaling crossroads. Hypertension (2008) 0.75
Tipping the extracellular matrix balance during heart failure progression: do we always go right? Cardiology (2010) 0.75
Beta-blockade in heart failure: adding SENIORS to the mix. Eur Heart J (2006) 0.75
Aging modifies the cardiac response to estrogen: a new dimension to hormone replacement therapy. Hypertension (2006) 0.75